Skip to main content

Clinical Trials Using MDM2 Inhibitor

Review the clinical trials studying mdm2 inhibitor on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-11 of 11

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Status: Active
Location: 29 locations
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
Status: Active
Location: 3 locations
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
Status: Active
Location: 3 locations
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
Status: Active
Location: See ClinicalTrials.gov
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Status: Active
Location: See ClinicalTrials.gov
KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF
Status: Active
Location: See ClinicalTrials.gov
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Status: Active
Location: See ClinicalTrials.gov
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Status: Active
Location: See ClinicalTrials.gov